Alves, D
Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of medications prescribed in the UK for managing type 2 diabetes and, in specific formulations, for weight management
In conclusion, Tirzepatide and Semaglutide effectively combine appetite control, slower digestion, and improved metabolism for weight loss, offering a groundbreaking method to manage obesity
These risks are compounded in a landscape where pharmacies are under pressure to meet rising demand, reduce delivery timeframes, and ensure absolute compliance
We can more easily show the impact of using a patent thicket strategy, where a drug manufacturer abuses the patent system through excessive and overlapping patents to increase the exclusivity period for their drug
Another meta-analysis, which looked at relevant data from multiple clinical studies, estimated that 40-70% of people on GLP-1 drugs will experience nausea at some point while taking the medication